Biotechnology company Alveus Therapeutics has raised $159.8 million to advance its next-generation therapies for obesity and metabolic diseases. Proceeds from the Series A financing will support Phase II clinical development of ALV-100, the company’s lead programme, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist. ALV-100 is a bifunctional […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!